Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases

Kitchen, Lynn W.; Vaughn, David W.

doi:10.1016/j.vaccine.2007.07.030

Cited by 40 publications

(46 citation statements)

References 92 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Speciesspecific epitopes appear to reside on the inner surface of the hexon. The protective effect of antibody-mediated immunity is demonstrated by the successful application, in the late 1950's, of formalin-inactivated Ad4 and Ad7 vaccines to protect US military recruits from Ad-related ARD [29]. Between 1971 and 1999, live oral vaccines for Ad4 and Ad7 controlled ARD.…”

Section: Adenovirus-specific Immunitymentioning

confidence: 99%

Clinical features and treatment of adenovirus infections

Lenaerts

Clercq

Naesens

2008

Reviews in Medical Virology

209

182

View full text Add to dashboard Cite

Adenoviruses (Ads) are common opportunistic pathogens that are rarely associated with severe clinical symptoms in healthy individuals. In contrast, in patients with compromised immunity, Ad infections often result in disseminated and potentially life-threatening disease. Among these are AIDS patients, individuals with hereditary immunodeficiencies and recipients of solid organ or haematopoietic stem cell transplants (HSCT) who receive immunosuppressive therapy. The latter account for the largest number of severe Ad infections. There is currently no formally approved antiviral therapy for the treatment of severe Ad keratoconjunctivitis and life-threatening Ad infections in immunocompromised patients. Here we update current knowledge on Ad biology, the clinical features observed in different patient groups and specific immune responses towards Ad infections. In addition, we review current and future treatment options, including: (i) the antiviral drugs cidofovir, ribavirin and new investigational compounds, as evaluated in the clinic or in relevant animal models, as well as (ii) novel immunotherapeutic strategies.

show abstract

Section: Adenovirus-specific Immunitymentioning

confidence: 99%

Clinical features and treatment of adenovirus infections

Lenaerts

Clercq

Naesens

2008

Reviews in Medical Virology

209

182

View full text Add to dashboard Cite

show abstract

“…Climate, ecological changes and international travel increase the risk of VEEV re-emergence [46, 70, 74]. Furthermore, the virus can also be easily prepared in large quantities and aerosolized as a potential biological weapon [74, 75]. The initial VEEV symptoms are similar to influenza and are difficult to diagnose [75].…”

Section: Dna-launched Vaccines For Alphavirusesmentioning

confidence: 99%

DNA-launched live-attenuated vaccines for biodefense applications

Pushko

Lukashevich

Weaver

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Summary A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.

show abstract

“…The Department of Defense (DoD) continued its own research, development, testing and evaluation (RDTE) programs, including separate programs for natural infectious disease threats (e.g., diarrheal pathogens, dengue) and biological weapons (e.g., anthrax, botulism, smallpox, plague, tularemia) [69,[72][73][74][75][76]. A few of the notable defense laboratories devoted to infectious-disease research include the Walter Reed Army Institute of Research, the Naval Health Research Center, the US Army Medical Research Institute of Infectious Diseases, and a set of overseas laboratories in Thailand, Peru, Egypt, and elsewhere.…”

Section: General Historymentioning

confidence: 99%

“…A few of the notable defense laboratories devoted to infectious-disease research include the Walter Reed Army Institute of Research, the Naval Health Research Center, the US Army Medical Research Institute of Infectious Diseases, and a set of overseas laboratories in Thailand, Peru, Egypt, and elsewhere. Notable vaccines produced with major DoD involvement include adenovirus, anthrax, hepatitis A, influenza A&B, meningococcal, pneumococcal, rubella, typhoid, typhus, and others [1,[68][69][70][71][72][73][74][75][76].…”

Section: General Historymentioning

confidence: 99%